TICKERNERD
Menu
ALTALTHealthcare · Biotechnology

ALT Stock Forecast: Altimmune, Inc. Price Predictions for 2026-2027

Last close, 28 Aug 2026
$3.11
−4.01% on the day

The 10 Wall Street analysts covering Altimmune, Inc. hold a median 12-month price target of $18 — +478.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 29 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$605.0M
Ticker Nerd rank
23 / 100
Median analyst target
$18
Analysts covering
10
Revenue$0.0−100.0% y/y
Operating income−$24.2M
Net income−$22.6M
Free cash flow−$21.0M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
0.0%
1M
+4.0%
YTD
−13.9%
1Y
−16.2%
From 52W high
−49.7%
From 52W low
+20.1%
$2.59
$6.18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Altimmune, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 29 Aug 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
76
Revisions
56
Quality
52
Size
51
Accruals
29
Value
28
Volatility
25
Momentum
15
Issuance
10

Growth (76): Sales and profits are climbing, and climbing faster than before.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00Oct 25Jan 26Apr 26Jul 26ALTHigh $28Median $18Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $11Median $18High $28

The green dot is the last close — the median target sits +478.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 June 2026Leerink PartnersInitiatesOutperform$10
18 May 2026HC Wainwright & Co.MaintainsBuy—
14 May 2026CitizensMaintainsMarket Outperform—
16 Mar 2026HC Wainwright & Co.MaintainsBuy—
6 Mar 2026B. Riley SecuritiesMaintainsBuy—
7 Nov 2025CitizensMaintainsMarket Outperform—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
10 Oct 2025HC Wainwright & Co.ReiteratesBuy—
13 Aug 2025B. Riley SecuritiesMaintainsBuy—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
13 Aug 2025UBSMaintainsBuy—
10 July 2025JMP SecuritiesMaintainsMarket Outperform—
27 June 2025HC Wainwright & Co.ReiteratesBuy—
3 Apr 2025HC Wainwright & Co.ReiteratesBuy—
2 Apr 2025Citizens Capital MarketsReiteratesMarket Outperform—
18 Mar 2025HC Wainwright & Co.ReiteratesBuy$12
14 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
28 Feb 2025William BlairInitiatesMarket Perform—
5 Feb 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ALT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Aug 2026, Altimmune, Inc. returned −16.2% against +19.9% for the S&P 500, dividends included.

ALT vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Oct 25Jan 26Apr 26Jul 26ALTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Altimmune, Inc. (ALT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.1×

Cheaper than 87% of US stocks

Price / sales
19514.5×

Cheaper than 1% of US stocks

Price / book
1.3×

Cheaper than 65% of US stocks

EV / EBITDA
−3.2×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−318493.5%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−28.9%

Higher than 27% of US stocks

Return on assets
−17.2%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Altimmune, Inc. (ALT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Altimmune, Inc. has a market value of $605.0M and an enterprise value of $314.7M.

  • Revenue in the twelve months to 31 Mar 2026: $36K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$91.1M, a −253002.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.93.

  • Free cash flow in the twelve months to 31 Mar 2026: −$71.7M, after $32K of capital spending.

  • Shares outstanding: 130.2M.

  • Trailing P/E: −3.1×; forward P/E: −4.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Altimmune, Inc. employs 57 people — $631.6 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 29 Aug 2026

Data provided by Twelve Data

Peers

ALT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALTAltimmune, Inc.$605.0M
23
BLSMBlossomhill Therapeutics, Inc.$599.4M
0
EIKNEikon Therapeutics, Inc.$594.0M
2
ARVNArvinas, Inc.$589.6M
84
SPRYARS Pharmaceuticals, Inc.$582.2M
12
RGNXREGENXBIO, Inc.$630.9M
54
VSTMVerastem, Inc.$634.2M
56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Altimmune, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALT news & analysis

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

Zacks Investment Research · 19 Aug 2026positive

Altimmune has advanced its drug pemvidutide into Phase III testing for metabolic dysfunction-associated steatohepatitis (MASH), supported by encouraging mid-stage data and regulatory backing, with a data readout expected in 2029.

Why it matters — The Phase III study represents a key clinical milestone for Altimmune's lead candidate, and the 2029 readout gives investors a clear timeline for a potentially significant catalyst.

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

Zacks Investment Research · 19 Aug 2026neutral

Zacks reports that Altimmune's stronger cash position supports its pemvidutide programs for MASH, AUD, and ALD, while noting that long timelines, funding needs, and competition remain risks.

Why it matters — An ALT watcher would care because the company's cash position underpins its pipeline progress, while execution risks around timelines, funding, and competition could affect the outlook for pemvidutide.

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Zacks Investment Research · 13 Aug 2026positive

Altimmune reported a narrower-than-expected Q2 loss. Its $519M in cash is expected to support operations into 2029, while its drug candidate pemvidutide advances across liver and AUD (alcohol use disorder) studies.

Why it matters — A narrower Q2 loss, extended cash runway, and progress in pemvidutide studies are key developments for Altimmune watchers tracking the company's financial health and pipeline.

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Altimmune, Inc. released the transcript of its Q2 2026 earnings call, as republished by Seeking Alpha. The item presents the official earnings-call discussion for that quarter.

Why it matters — The earnings-call transcript offers ALT watchers the company's own commentary on its Q2 2026 results and outlook.

Altimmune Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026positive

Altimmune has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for MASH and is advancing plans for later-stage development in alcohol use disorder.

Why it matters — The start of a Phase III trial and expansion into a new indication mark key clinical milestones for Altimmune's lead drug candidate.

FAQ

Frequently asked questions about ALT stock

What is the ALT stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Altimmune, Inc. have a median 12-month price target of $18, with estimates ranging from $11 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALT stock a buy right now?

Of the 10 analysts covering Altimmune, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Altimmune, Inc. 23 out of 100 across roughly 4,600 US stocks as at 29 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALT?

As at 29 Aug 2026, Altimmune, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (76 of 100).

Will ALT stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +478.8% from the last close, and Ticker Nerd's factor model ranks Altimmune, Inc. 23 out of 100 as at 29 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALT stock forecast for 2030?

No analyst covering Altimmune, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $28 over the next 12 months.

How has ALT stock performed over the past year?

Altimmune, Inc. returned -16.2% over the 12 months to 28 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Altimmune, Inc. do?

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies for obesity, metabolic disorders, and serious liver diseases.

What is the latest news on ALT?

The most recent item we track (Zacks Investment Research, 19 Aug 2026): "Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus". Altimmune has advanced its drug pemvidutide into Phase III testing for metabolic dysfunction-associated steatohepatitis (MASH), supported by encouraging mid-stage data and regulatory backing, with a data readout expected in 2029.

Company

About Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies for obesity, metabolic disorders, and serious liver diseases. The company’s lead product candidate, pemvidutide, is a dual GLP-1 and glucagon receptor agonist being studied for conditions such as metabolic dysfunction-associated steatohepatitis, alcohol use disorder, alcohol-associated liver disease, and obesity. Altimmune is also developing HepTcell, an immunotherapeutic program designed for chronic hepatitis B. Through these programs, Altimmune operates at the intersection of metabolic medicine, hepatology, and immunotherapy, with a pipeline aimed at addressing complex diseases that currently have limited treatment options. The company is headquartered in Gaithersburg, Maryland.

CEO Mr. Jerome Benedict Durso · 57 employees · United States · https://altimmune.com